Literature DB >> 22503131

Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: effect of 5-AZA treatment.

S Gutierrez-Cosío1, L de la Rica, E Ballestar, C Santamaría, L I Sánchez-Abarca, T Caballero-Velazquez, B Blanco, C Calderón, C Herrero-Sánchez, S Carrancio, L Ciudad, C Cañizo, J F San Miguel, J A Pérez-Simón.   

Abstract

PRAME is a tumor associated antigen (TAA) of particular interest since it is widely expressed by lymphoid and myeloid malignancies. Several studies have associated high PRAME RNA levels with good prognosis in acute myeloid leukemia (AML). PRAME expression is regulated at the epigenetic level. For this reason inhibitors of DNA methylation, such as 5-azacytidine, can modulate the expression of this TAAs. In the current study we analyzed the effect of 5-azaC on the expression of PRAME in blasts versus CD34+ cells from healthy donors in an attempt to increase its expression, thus inducing a potential target for therapeutic strategies.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22503131     DOI： 10.1016/j.leukres.2012.02.030

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  6 in total

1.  Methylation pattern of preferentially expressed antigen of melanoma in acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Ya-Zhen Qin; Yan-Huan Zhang; Xiao-Ying Qin; Hong-Hu Zhu
Journal:  Oncol Lett       Date:  2017-02-28       Impact factor: 2.967

2.  Both Methylation and Copy Number Variation Participated in the Varied Expression of PRAME in Multiple Myeloma.

Authors:  Lu Yang; Feng-Ting Dao; Yan Chang; Ya-Zhe Wang; Ling-Di Li; Wen-Min Chen; Ling-Yu Long; Yan-Rong Liu; Jin Lu; Kai-Yan Liu; Ya-Zhen Qin
Journal:  Onco Targets Ther       Date:  2020-07-31       Impact factor: 4.147

3.  PRAME expression and promoter hypomethylation in epithelial ovarian cancer.

Authors:  Wa Zhang; Carter J Barger; Kevin H Eng; David Klinkebiel; Petra A Link; Angela Omilian; Wiam Bshara; Kunle Odunsi; Adam R Karpf
Journal:  Oncotarget       Date:  2016-07-19

4.  Priming of PRAME- and WT1-specific CD8+ T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy.

Authors:  Willemijn van den Ancker; Jurjen M Ruben; Theresia M Westers; Dewi Wulandari; Hetty J Bontkes; Erik Hooijberg; Anita G M Stam; Saskia J A M Santegoets; Gert J Ossenkoppele; Tanja de Gruijl; Arjan van de Loosdrecht
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110

5.  In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME).

Authors:  Dmitry Pankov; Ludvig Sjöström; Teja Kalidindi; Sang-Gyu Lee; Kjell Sjöström; Rui Gardner; Michael R McDevitt; Richard O'Reilly; Daniel L J Thorek; Steven M Larson; Darren Veach; David Ulmert
Journal:  Oncotarget       Date:  2017-07-26

6.  PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer.

Authors:  Ghaneya Al-Khadairi; Adviti Naik; Remy Thomas; Boshra Al-Sulaiti; Shaheen Rizly; Julie Decock
Journal:  J Transl Med       Date:  2019-01-03       Impact factor: 5.531
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.